MedTrace Logo

Lamotrigine for Ketamine Dependence Trial

NCT02556060 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-02-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy of lamotrigine in the treatment of ketamine dependence in a double-blind, placebo controlled design.

Conditions

Interventions

DRUG

Lamotrigine

Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks

DRUG

Placebo

Same dosing schedule as study drug

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Taipei City Hospital

    lead OTHER_GOV

Principal Investigators

  • Shih-Ku Lin, MD · Taipei City Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-05-01
Completion
2017-05-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02556060 on ClinicalTrials.gov